Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRDC002 in the Diagnosis of Patients With PSMA-positive Recurrent or Metastatic Prostate Cancer
NCT07236112Phase 1Active, not recruiting
- Sponsor
- C Ray Therapeutics
- Start
- Feb 2026
- Primary completion
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of TRDC002 in prostate cancer (PCa) (2 arms), sponsored by C Ray Therapeutics. Primary endpoint: Safety and Tolerability of TRDC002 at 3 days. Started Feb 2026; status: active, not recruiting.
02
Drugs
TRDC002
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT07236112.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07236112.